GlassScriptPhysician profile
Genene M Bekele
NPI 1780733568
$5,773.86
in general payments reported to CMS, 2019-2025
36 companies · $899 in 2025
The $899 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,776 · 2023: $1,861 · 2024: $1,238 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,954 · Education: $43.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,953.96 |
| Education | $43.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,264.92 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Beta Bionics, INC. | $409.67 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Medtronic, INC. | $392.97 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Lilly USA, LLC | $392.12 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $348.11 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $295.35 | 2022-2024 | |
| Dexcom, INC. | $261.92 | 2022-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $236.50 | 2022-2023 | Korlym |
| Insulet Corporation | $205.54 | 2022-2023 | Omnipod |
| Abbvie INC. | $204.35 | 2022-2025 | Synthroid, Ubrelvy |
| Nevro Corp. | $192.71 | 2022-2024 | Senza |
| Tandem Diabetes Care, INC. | $192.25 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $188.38 | 2022-2025 | Prolia, Evenity, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.78 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $117.62 | 2022-2023 | Steglatro, Segluromet, Steglujan |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Genene Bekele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.